Access Pharmaceuticals

Contact

• 2600 Stemmons Freeway,
• Suite 176
• Dallas, TX 75207-2107
• Tel: (214) 905-5100
• Fax: (214) 905-5101

Sign up for news alerts!

Business Development

The Business Development team at Access Pharmaceuticals is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for for our oncology and dermatology products, as well as for our nanopolymer technologies, including Cobalamin™ for oral drug delivery, Cobalamin™ for disease targeting, and SEPA, Access’ nail and transdermal drug delivery technology.

MuGard™ is our product for oral mucositis which has received US FDA marketing allowance. Access has licensing agreements with Milestone Biosciences (North America), SpePharm (Europe) and RHEI Pharmaceuticals (certain Asian territories), and is seeking commercial partners in other territories.

ProLindac™ is our major chemotherapeutic compound, currently in Phase 2 clinical development. Access has licensed ProLindac to Nanjing Aosaikang Medicinal Group Co., Ltd for development and commercialization in China, and is seeking codevelopment partners for other territories.

We are open to discussing arrangements of all types. To learn more about our products and capabilities please contact Phillip Wise by sending an email to the address below.

phillip.wise@accesspharma.com